Compare Logitech International SA (LOGI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Twist Bioscience Corp — how do they compare? Logitech International SA trades at $98.27 (market cap $14.46B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Logitech International SA is the larger of the two by market cap, and Logitech International SA pays a 1.63% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Twist Bioscience Corp for 27 Days on average.
| LOGI | TWST | |
|---|---|---|
Market Cap | $14.46B | $10.08B |
Volume | 349,547 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $126.69 | $205.00 |
52-Week Low | $85.84 | $25.45 |
Typical Hold Time | 92 Days | 27 Days |
Enterprise Value | $12.79B | $10.01B |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.50, down 0.67% on the day, with a neutral technical signal and key support at $100. The company demonstrates strong fundamentals with a 16.28% net income margin and consistent earnings beats in recent quarters. Recent product launches like the Zone Vibe Pro headset and partnership with SEGA for Crazy Taxi: World Tour highlight ongoing innovation. Cash flow trends show robust operational performance, with 2025 operating cash flow of $842.56 million.
The outlook is cautiously optimistic, supported by a consensus price target of $107.00 implying modest upside. Investment opportunities include sustained profitability and strategic growth initiatives, while risks involve competitive pressures and potential supply chain disruptions as noted in recent CEO commentary. Analyst sentiment is mixed with a Hold-heavy consensus, reflecting balanced near-term expectations.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
